PATUSKY CHRISTOPHER

Director Patusky sells 2,910 UTHR shares at $569.00; retains 1,490 shares after -66.1% reduction in holdings

Christopher Patusky, a director, sold 2,910 shares of United Therapeutics at $569.00 on 2026-04-24, reducing his position from 4,400 to 1,490 shares. This represents a substantial -66.1% reduction in his equity stake in the company. His prior five sales at UTHR all occurred on 2025-03-19 and were uniformly well-timed at the 90-day mark, with negative 90-day returns ranging from -6.8% to -8.4%, indicating consistent pattern recognition for downside moves. The stock has appreciated +21.0% over the past 90 days and currently trades at $567.16, only -4.4% below its 52-week high of $592.98, suggesting Patusky is selling into a strong recent rally rather than at historically depressed levels. This substantial position reduction merits investor attention given both his historical accuracy in timing downturns at this ticker and the current elevated price backdrop.

Director Patusky sells 5,000 shares (84.7% of holdings) at $310.72 avg for $1.55M on same day stock down 15.9% in 30 days

Christopher Patusky, a Director of United Therapeutics, executed 7 separate sales on March 19, 2025, totaling 5,000 shares for $1,553,584.58, reducing his holdings from 5,900 to 900 shares. This represents an 84.7% reduction in his stake. The timing is noteworthy: the sales occurred as the stock traded at $313.60, which is 23.5% below its 52-week high of $410.00, and within a 30-day window showing -15.9% decline and a 90-day decline of -12.8%. Examining his prior transaction history at UTHR (5 recent sells on 2025-01-10), those trades showed 30-day returns of -4.4% to -3.0%, indicating the stock has continued its recent downtrend after his earlier sales. His cross-ticker track record shows 8 prior sells with a 0.00% well-timed rate at the 90-day mark, suggesting his historical sell timing has not positioned him ahead of declines. The company's fundamentals remain solid (P/E of 10.66, annual revenue growth of +23.6%, $309.1M net income), but the director's large-scale exit during an extended drawdown merits investor attention.

Director Patusky sells 5,000 UTHR shares (84.7% of holdings) in 6 tranches for $1.8M at avg $361.61

Christopher Patusky, Director of United Therapeutics, executed 6 separate sales totaling 5,000 shares for $1,808,071.86 on 2025-01-10, reducing his position from 5,900 to 900 shares and liquidating 84.7% of his holdings. The blended average price of $361.61 sits just below the current price of $362.88, and the stock remains -11.5% from its 52-week high of $410.00. His prior two sales at UTHR (2024-09-04 and 2024-09-03) saw subsequent 90-day gains of +4.4% and +2.7%, respectively, indicating a pattern of selling before upside moves. UTHR's fundamentals show strong growth (+20.2% annual revenue growth) and attractive valuation (P/E 14.59), though the large sale magnitude and near-complete portfolio reduction warrant attention to whether this reflects personal liquidity needs, tax planning, or shifting conviction.

Director Patusky sells 5,000 shares (84.7% of holdings) across 2 transactions for $1,771,647.38

Christopher Patusky, a Director at United Therapeutics, executed 2 separate sales totaling 5,000 shares for $1,771,647.38 on September 3–4, 2024, reducing his holdings from 5,900 shares to 900 shares—an 84.7% reduction in his position. The sales occurred at prices ($360.31 and $353.36) near the 52-week high of $363.55, with the stock currently trading at $350.01 and having appreciated 27.3% over the prior 90 days. The company shows robust fundamentals: $714.9M in latest-quarter revenue, a net income of $278.1M, 20.2% annual revenue growth, and a P/E of 14.56. The substantial reduction in director holdings warrants attention, though the lack of context on whether this sale was discretionary or scheduled under a 10b5-1 plan is material to interpreting intent.